The impact of IVIG therapy on live birth rates in women with RPL: A systematic review and meta-analysis

Intravenous immunoglobulin (IVIG) is used in reproductive failure problems, and particularly in RPL women with immune disorders. In this meta-analysis, we assessed the outcomes of studies on RPL women with abnormal immunologic parameters who underwent IVIG therapy, where live birth rates were appraised as treatment outcome. An electronic search was conducted in Medline (PubMed), ProQuest, EMBASE, Scopus, Google Scholar, and Web of science. The process of the selection of studies according to our inclusion criteria, methodological quality assessment, and data extraction was performed by two reviewers independently, which resulted in the inclusion of five studies (Two cohorts, and three quasi experimental studies). Data analyses were performed by RevMan 5.2 software. The results of our meta-analysis demonstrated a meaningful difference in live birth rate of quasi-experimental (OR = 8.64, 95% CI =4.36–17.15, P < 0.00001) and cohort studies (OR = 50.44, 95% CI =15.28–166.58, P < 0.00001) in the IVIG group, in comparison to the control group. Conclusively, IVIG may be an efficient therapeutic agent in RPL women nominated for immune disorders. Nonetheless, more studies are recommended to further reveal the effectiveness of IVIG in these patients.